{
    "ticker": "GLYC",
    "name": "GlycoMimetics, Inc.",
    "description": "GlycoMimetics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for patients with cancer and rare diseases. Founded in 2003 and headquartered in Rockville, Maryland, GlycoMimetics leverages its proprietary glycomimetic technology platform to create innovative drug candidates that target specific glycan-protein interactions involved in disease processes. The company's lead product candidate, uproleselan (GMI-1271), is a novel E-selectin antagonist currently being evaluated in clinical trials for the treatment of acute myeloid leukemia (AML) and other hematologic malignancies. GlycoMimetics is also exploring the potential of its drug candidates in various serious conditions, including sickle cell disease and certain solid tumors. The company is committed to advancing its pipeline through rigorous research and development, collaborating with leading academic institutions and industry partners to bring transformative therapies to patients. GlycoMimetics aims to improve treatment outcomes and quality of life for patients suffering from challenging diseases, addressing significant unmet medical needs in oncology and beyond.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Rockville, Maryland, USA",
    "founded": "2003",
    "website": "https://www.glycomimetics.com",
    "ceo": "Rachel King",
    "social_media": {
        "twitter": "https://twitter.com/GlycoMimetics",
        "linkedin": "https://www.linkedin.com/company/glycomimetics/"
    },
    "investor_relations": "https://investors.glycomimetics.com",
    "key_executives": [
        {
            "name": "Rachel King",
            "position": "CEO"
        },
        {
            "name": "Helen Thackray",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Clinical Candidates",
            "products": [
                "Uproleselan (GMI-1271)"
            ]
        }
    ],
    "seo": {
        "meta_title": "GlycoMimetics, Inc. | Innovative Therapies for Cancer and Rare Diseases",
        "meta_description": "Learn about GlycoMimetics, Inc., a biotechnology company focused on developing innovative therapies for cancer and rare diseases through its proprietary glycomimetic technology.",
        "keywords": [
            "GlycoMimetics",
            "Biotechnology",
            "AML",
            "Uproleselan",
            "Cancer Therapies"
        ]
    },
    "faq": [
        {
            "question": "What does GlycoMimetics focus on?",
            "answer": "GlycoMimetics focuses on developing novel therapies for cancer and rare diseases."
        },
        {
            "question": "What is Uproleselan?",
            "answer": "Uproleselan (GMI-1271) is GlycoMimetics' lead product candidate, a novel E-selectin antagonist being evaluated for acute myeloid leukemia."
        },
        {
            "question": "Where is GlycoMimetics headquartered?",
            "answer": "GlycoMimetics is headquartered in Rockville, Maryland, USA."
        },
        {
            "question": "When was GlycoMimetics founded?",
            "answer": "GlycoMimetics was founded in 2003."
        }
    ],
    "competitors": [
        "NVS",
        "ABBV",
        "BMY",
        "VRTX"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "GILD",
        "CELG"
    ]
}